| Autor: |
Hilczer, Maciej, Walczak, Mieczysław |
| Předmět: |
|
| Zdroj: |
Pediatric Endocrinology, Diabetes & Metabolism; 2024, Vol. 30 Issue 2, p49-50, 2p |
| Abstrakt: |
This article discusses the history and development of human growth hormone (hGH) therapy. It begins by tracing the discovery of growth-promoting substances in the pituitary glands of rats in 1921 and the subsequent extraction of hGH from human pituitary glands in the 1950s. The article then highlights the discontinuation of pituitary-derived hGH due to the risk of Creutzfeldt-Jakob disease in 1985 and the introduction of recombinant hGH (rhGH) through genetic engineering. The use of rhGH has expanded to include various conditions such as GH deficiency, Turner syndrome, and Prader-Willi syndrome. The article also mentions ongoing research on long-acting rhGH formulations that could potentially reduce the frequency of injections. The safety and efficacy of rhGH therapy are emphasized, along with the need for continued surveillance and evaluation of new treatment options. [Extracted from the article] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
